Glial cell line-derived neurotrophic factor does not enter normal mouse brain
- PMID: 12672550
- DOI: 10.1016/s0304-3940(03)00007-7
Glial cell line-derived neurotrophic factor does not enter normal mouse brain
Abstract
Glial cell line-derived neurotrophic factor (GDNF) is produced both in the central nervous system (CNS) and the periphery. Effective in ameliorating neurodegeneration in several animal models of CNS disease, its promise as a therapeutic agent would be greatly enhanced if it readily crossed the blood-brain barrier (BBB) in unmodified form. Here, we used the sensitive techniques of multiple-time regression analysis and ex-vivo perfusion in blood-free buffer to examine the entry of (125)I-GDNF into mouse brain. The integrity of GDNF in blood and brain was examined by high performance liquid chromatography and the physicochemical properties determining permeability were measured by octanol/buffer partition coefficient and hydrogen bonding. The efflux of (125)I-GDNF was determined to test for the presence of a bidirectional transport system. The results show that (125)I-GDNF differs from other peptides and polypeptides in that it does not enter brain any faster than (99m)Tc-albumin, an effect that cannot be explained by degradation, rapid efflux, protein binding, or inadequate lipophilicity. Thus, GDNF shows a different type of interaction with the BBB. In normal mice, the BBB functions as a substantial physical barrier; in pathological or traumatic situations when the barrier is partially disrupted, the lack of restriction by a saturable transport system could make GDNF a suitable candidate for peripheral delivery in promoting neuroregeneration.
Similar articles
-
Enhanced delivery of [125I]glial cell line-derived neurotrophic factor to the rat CNS following osmotic blood-brain barrier modification.Neurosci Lett. 1996 Dec 20;220(3):187-90. doi: 10.1016/s0304-3940(96)13265-1. Neurosci Lett. 1996. PMID: 8994224
-
Different mechanisms influencing permeation of PDGF-AA and PDGF-BB across the blood-brain barrier.J Neurochem. 2003 Oct;87(1):7-12. doi: 10.1046/j.1471-4159.2003.01933.x. J Neurochem. 2003. PMID: 12969247
-
Circulating TGF-beta1 does not cross the intact blood-brain barrier.J Mol Neurosci. 2003;21(1):43-8. doi: 10.1385/JMN:21:1:43. J Mol Neurosci. 2003. PMID: 14500993
-
A commentary on glial cell line-derived neurotrophic factor (GDNF). From a glial secreted molecule to gene therapy.Biochem Pharmacol. 1999 Jan 15;57(2):135-42. doi: 10.1016/s0006-2952(98)00280-9. Biochem Pharmacol. 1999. PMID: 9890561 Review.
-
Motoneurons crave glial cell line-derived neurotrophic factor.Exp Neurol. 2004 Dec;190(2):263-75. doi: 10.1016/j.expneurol.2004.08.012. Exp Neurol. 2004. PMID: 15530868 Review.
Cited by
-
Astrocytes in Neuropsychiatric Disorders: A Review of Postmortem Evidence.Adv Neurobiol. 2021;26:153-172. doi: 10.1007/978-3-030-77375-5_8. Adv Neurobiol. 2021. PMID: 34888835 Review.
-
GDNF--a potential target to treat addiction.Pharmacol Ther. 2009 Apr;122(1):9-18. doi: 10.1016/j.pharmthera.2008.12.001. Epub 2008 Dec 24. Pharmacol Ther. 2009. PMID: 19136027 Free PMC article. Review.
-
Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?Front Neurosci. 2010 Jun 11;4:32. doi: 10.3389/fnins.2010.00032. Front Neurosci. 2010. PMID: 20592948 Free PMC article.
-
Ultrasound combined with glial cell line-derived neurotrophic factor-loaded microbubbles for the targeted treatment of drug addiction.Front Bioeng Biotechnol. 2022 Aug 15;10:961728. doi: 10.3389/fbioe.2022.961728. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 36046678 Free PMC article.
-
Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction.BMC Psychiatry. 2019 Aug 16;19(1):254. doi: 10.1186/s12888-019-2231-3. BMC Psychiatry. 2019. PMID: 31420036 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources